{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-foot/management/management/","result":{"pageContext":{"chapter":{"id":"a11a4a32-6cc1-5c40-8396-099a218e1487","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field b4422db7-3e2c-4d9d-8243-0e9687f13453 --><h2>Scenario: Management of fungal skin infection - foot</h2><!-- end field b4422db7-3e2c-4d9d-8243-0e9687f13453 -->","summary":"Covers the management of people with suspected fungal foot infection.","htmlStringContent":"<!-- begin item 61fc5621-3d46-4710-9e12-43034a14712d --><!-- begin field 73e1a030-6094-4d51-b998-acbd00874236 --><p>From age 1 month onwards.</p><!-- end field 73e1a030-6094-4d51-b998-acbd00874236 --><!-- end item 61fc5621-3d46-4710-9e12-43034a14712d -->","topic":{"id":"32650c82-f347-5933-adc6-d0da00f3d764","topicId":"35b0fa0c-8988-453f-af54-60cd595d29ad","topicName":"Fungal skin infection - foot","slug":"fungal-skin-infection-foot","lastRevised":"Last revised in April 2018","chapters":[{"id":"66fe4516-176d-5ffc-aebd-99a58afbd57c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5231c18b-820c-586e-87f0-5527574f70d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e2b3169b-582d-5dda-b94f-73ccd139eede","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e1fd155-8f48-5bf7-a40c-4d2931a41736","slug":"changes","fullItemName":"Changes"},{"id":"8249fd1f-7c27-535b-a721-9e280d761ea5","slug":"update","fullItemName":"Update"}]},{"id":"e4ea5f16-99ef-5247-87e9-141b06d8b21a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"524d92eb-2792-5543-a6d9-78e4f825cf22","slug":"goals","fullItemName":"Goals"},{"id":"a678e6e3-5a4b-55cb-b7d6-c6ab9580eda2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"44708a93-b41d-5827-9293-650b191df0b0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d578224-3b80-58f6-9894-5c90e41c1b44","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a029f7b6-3344-51e6-ab22-bafdf196a4b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b487a461-1526-54bb-a2df-4e2e0562293d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0e034d35-5e8d-5db3-a518-77103caa73c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"73e18fb0-6f03-51ed-bddf-355959375e75","slug":"definition","fullItemName":"Definition"},{"id":"a33dea25-362f-5128-9c14-d178ef837bfe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"a4167228-e44b-560b-8406-20294a5b8e42","slug":"prevalence","fullItemName":"Prevalence"},{"id":"91f3fb6f-6926-547c-830c-dd963749fb55","slug":"complications","fullItemName":"Complications"},{"id":"8373f46b-763e-53e3-9ea8-90cd767d66e6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"090da929-a640-586e-a803-a47b38656e1d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"024c307f-3650-539d-b0b4-4f1c4a8db49e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e3544fc8-cba9-524d-aed2-f28ae6f802e8","slug":"assessment","fullItemName":"Assessment"},{"id":"3ad14837-2b4c-58ab-b5c5-456d63d403ae","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"db051fa9-f61e-5787-bd5d-b2ff4a77ba85","fullItemName":"Management","slug":"management","subChapters":[{"id":"a11a4a32-6cc1-5c40-8396-099a218e1487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"27a2a883-b20f-5b25-825b-3bc5b02c1f77","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"476702d7-9e1a-5dfd-b3b0-899ebce5130b","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"e3c1f25f-1a76-53af-aef4-b39eecdf04d7","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"4f73cab3-f311-54bd-beac-8bb860f26e2f","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"aaec6565-5327-5bd4-bc06-a1442065c1bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c64c0494-1e71-5960-a8c9-a05141d2801c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"265ba112-5e5e-59c8-8569-29d1a263263d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e7088451-abf0-5e2f-a546-109de8062cbf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"96559e5f-dca9-5c90-af8c-c1182e5d3306","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd075cd9-9444-5680-bd23-a168ebe2b5a2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"49b473c6-a745-5480-9602-1224549611f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"65b0f432-1967-593c-a9f7-2326776f4e83","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db051fa9-f61e-5787-bd5d-b2ff4a77ba85","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0a674538-3bd2-5ac0-9dc8-ceca89d9e2e7","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field 37c54e19-c019-4dde-b496-f565a3aeb659 --><h3>How should I initially manage fungal foot infection?</h3><!-- end field 37c54e19-c019-4dde-b496-f565a3aeb659 -->","summary":null,"htmlStringContent":"<!-- begin item 2c1e3767-12a6-4e75-bb79-038c4338ee7b --><!-- begin field 58710d14-65d5-4c0d-9551-b545ee85fd1a --><ul><li><strong>Advise on self-care management strategies:</strong><ul><li>Wear well-fitting, non-occlusive footwear that keeps the feet cool and dry. Consider replacing old footwear which could be contaminated with fungal spores.</li><li>Maintain good foot hygiene by wearing a different pair of shoes every 2–3 days.</li><li>Wear cotton, absorbent socks.</li><li>Avoid scratching affected skin, as this may spread infection to other sites.</li><li>After washing the feet, dry thoroughly, especially between the toes.</li><li>Do not share towels, and wash them frequently, to reduce the risk of transmission.</li><li>Wear protective footwear when using communal bathing places, locker rooms, and gymnasiums, to reduce the risk of transmission.</li><li>If a child is affected, it is not necessary to exclude them from school or nursery.</li></ul></li><li><strong>Provide information on sources of advice and support, such as:</strong><ul><li>The NHS information on <a data-hyperlink-id=\"5ec9f885-742b-45ae-b40b-a8f70158a0c8\" href=\"https://www.nhs.uk/conditions/athletes-foot/\" target=\"_blank\">Athlete's foot</a>.</li><li>The Patient information leaflet <a data-hyperlink-id=\"28e455f5-cf08-45a2-8f79-a8f70158a0d1\" href=\"https://patient.info/health/fungal-infections/athletes-foot-tinea-pedis\" target=\"_blank\">Athlete's foot (Tinea pedis)</a> available on the <a data-hyperlink-id=\"2f220e28-a748-4b59-b378-a8f70158a0d1\" href=\"https://patient.info/\" target=\"_blank\">www.patient.info</a> website.</li></ul></li><li><strong>Advise treatment with a topical antifungal cream </strong>if there is mild, non-extensive disease in children and adults.<ul><li>Options include terbinafine cream or an imidazole such as clotrimazole, miconazole, or econazole cream (available over-the-counter for specific age-groups).<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/topical-antifungals/\">Topical antifungals</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/\">Prescribing information</a> for more information on different preparations (which are licensed for different age-groups), application and duration of treatment.</li></ul></li><li>Alternative options include over-the-counter undecenoic acid cream or topical preparations containing tolnaftate.</li><li>Advise that the use of other topical treatments such as tea tree oil is not recommended.</li><li>Advise that treatment with a topical antifungal cream may be repeated in the future, if there is a good response to topical treatment and there are recurrent episodes of mild, non-extensive disease.</li></ul></li><li><strong>Consider prescribing a mildly-potent topical corticosteroid in addition, </strong>if there is associated marked inflammation, such as:<ul><li>Hydrocortisone 1% cream to be applied once daily for a maximum of 7 days.</li><li>Advise that a topical corticosteroid preparation should not be used alone on skin lesions.<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more prescribing information.</li></ul></li></ul></li><li><strong>If an adult has severe or extensive disease, consider prescribing oral antifungal treatment </strong>if there is:<ul><li>A positive skin sample fungal microscopy or culture result.</li><li>A strong clinical suspicion of fungal foot infection before mycology results are back, depending on clinical judgement.</li><li>A negative mycology result, but clinical features are very suggestive of infection.<ul><li>Arrange for repeat <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/diagnosis/assessment/#taking-skin-samples\">skin sampling</a>, and start oral antifungal treatment.</li></ul></li></ul></li><li><strong>If oral antifungal treatment is offered in primary care:</strong><ul><li>Consider prescribing terbinafine first-line.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li><li>Consider prescribing oral itraconazole or oral griseofulvin if terbinafine is not tolerated or is contraindicated.<ul><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/oral-griseofulvin/\">Oral griseofulvin</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li></ul></li><li><strong>If a child has severe or extensive disease, </strong>arrange <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/management/management/#follow-up-referral\">referral</a> to a paediatric dermatologist.</li><li><strong>If there is concomitant suspected fungal nail, hand, or groin infection,</strong> arrange appropriate management. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-nail-infection/\">Fungal nail infection</a> and <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-body-groin/\">Fungal skin infection - body and groin</a> for more information.</li><li><strong>Advise the person to arrange for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/management/management/#follow-up-referral\">follow-up</a> if there is an inadequate response to initial treatment.</strong></li></ul><!-- end field 58710d14-65d5-4c0d-9551-b545ee85fd1a --><!-- end item 2c1e3767-12a6-4e75-bb79-038c4338ee7b -->","subChapters":[{"id":"43f98e3f-2692-5543-b5d8-240ec8acd008","slug":"basis-for-recommendation-605","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 89cb08fc-e964-47ee-93e3-6d4b16ef307b --><h4>Basis for recommendation</h4><!-- end field 89cb08fc-e964-47ee-93e3-6d4b16ef307b -->","summary":null,"htmlStringContent":"<!-- begin item 60581ba0-b6e8-4d6c-a7e6-ee52df56d1aa --><!-- begin field 72e33f56-a626-45a7-a3c6-8c44ca99ebf5 --><p>The recommendations on initial management are largely based on the Public Health England (PHE) publications <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>] and <em>Health protection in schools and other childcare facilities</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2018</a>], two Cochrane systematic reviews <em>Topical treatments for fungal infections of the skin and nails of the foot</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Crawford and Hollis, 2007</a>] and <em>Oral treatments for fungal infections of the skin of the foot (Review)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Bell-Syer et al, 2012</a>], a meta-analysis of different topical antifungals in the treatment of fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Rotta et al, 2013</a>], and expert opinion in a review article on fungal foot infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>], review articles on fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>], and on corticosteroid-modified fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Verma, 2017</a>].</p><h5>Advice on self-care strategies</h5><ul><li>The recommendations on self-management are based on expert opinion in the PHE document on health protection in schools and other childcare facilities [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2018</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].<ul><li>The PHE document states that exclusion is not needed from school or other childcare facilities, but appropriate self-care measures and antifungal treatment should be started.</li></ul></li></ul><h5>Offering topical antifungal treatment</h5><ul><li>The recommendations on topical antifungal treatments are largely based on a Cochrane systematic review of topical antifungal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Crawford and Hollis, 2007</a>], a meta-analysis of the efficacy of topical antifungal treatments for fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Rotta et al, 2013</a>], and expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>]. <ul><li>The Cochrane systematic review analyzed randomized controlled trials (RCTs) of fungal foot infections and found similar pooled risk ratios of treatment failure for allylamines including terbinafine, azoles, tolnaftate, and undecanoates.<ul><li>Meta-analysis of 11 RCTs comparing allylamines and azoles showed a risk ratio of treatment failure of 0.63 in favour of allylamines, such as terbinafine.</li><li>There was no evidence to support the use of tea tree oil, and it did not show a greater benefit than placebo.</li></ul></li><li>This is supported by a mixed-treatment comparison meta-analysis which combined direct and indirect data from 65 RCTs (n = 7629) of fungal infections of the foot as well as body and groin.<ul><li>It found no statistically significant differences in the outcome of mycological cure for different topical antifungal agents up to 7 days after the completion of treatment, however, it found allylamines including terbinafine were significantly more efficacious than clotrimazole at maintaining mycological cure at least 14 days after completion of treatment.</li><li>It notes that allylamines are fungicidal compared with azoles which are fungistatic, and concludes that allylamines can reduce the frequency of relapse episodes and improve the chances of sustained cure.</li><li>CKS notes various limitations of the study, including the fact that comparisons were made with different drug preparations, concentrations, regimens, and durations of treatment, and data were combined from studies of fungal infections of the feet, body, and groin. In addition, studies often involved short follow-up periods, only 51% of studies were noted to have satisfactory blinding, and no cost-effectiveness study was undertaken.</li></ul></li><li>Expert opinion in the PHE publication supports the use of topical terbinafine first-line for fungal foot infection, and states that one week duration of this treatment is as effective as four weeks' duration of an azole.</li></ul></li></ul><h5>Offering topical corticosteroid treatment</h5><ul><li>The recommendation to prescribe a mildly-potent topical corticosteroid in addition to a topical antifungal preparation if there are signs of inflammation is extrapolated from expert opinion in review articles, as short-term use can reduce inflammation and symptoms of pain and itch while minimizing the risk of corticosteroid-related adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].</li><li>The recommendation to prescribe a topical corticosteroid separately to the topical antifungal is pragmatically based on what CKS considers to be good clinical practice, as this allows the corticosteroid to be used short-term, while the antifungal may be continued longer term depending on the recommended frequency and duration for each specific antifungal preparation.</li><li>The recommendation to avoid topical corticosteroid monotherapy is based on expert opinion in review articles.<ul><li>Topical corticosteroid use may cause the development of tinea incognito, where there is alteration of the morphology of fungal infection lesions, with flattening of the edge and loss of surface scale, which then makes clinical diagnosis more difficult [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>].</li><li>Furthermore, topical corticosteroid monotherapy does not eliminate fungus from the skin surface. As a result, fungal lesions may spread and proliferate, and there may be treatment failure and the development of antifungal resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Verma, 2017</a>].</li></ul></li><li>The recommendation on prescribing a mildly-potent topical corticosteroid for 7 days maximum is extrapolated from the manufacturer's Summary of Product Characteristics (SPC) for the combination product containing miconazole nitrate 2% and hydrocortisone 1% cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI Medicines Compendium, 2013</a>].</li></ul><h5>Prescribing oral antifungal treatment</h5><ul><li>The recommendation to prescribe oral antifungal treatment if there is severe or extensive disease is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].</li><li>The recommendation to consider prescribing oral antifungal treatment before fungal culture results are available is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>].</li><li>The recommendation to consider prescribing oral antifungal treatment if there is a strong clinical suspicion but negative culture results is extrapolated from expert opinion in a review article, which states that macerated or vesiculobullous lesions may be co-infected with gram-negative bacteria which reduce culture sensitivity, and therefore negative mycology results do not exclude the possibility of underlying fungal infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].</li><li>The recommendation to prescribe oral terbinafine first-line is based on a Cochrane review of 15 RCTs (n = 1438) of oral antifungal treatment which assessed the primary outcome of mycological cure rates of fungal foot infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Bell-Syer et al, 2012</a>].<ul><li>Two RCTs (n = 71) comparing oral terbinafine and griseofulvin produced a pooled risk ratio of 2.26 in favour of terbinafine.</li><li>No significant difference was found between terbinafine and itraconazole cure rates, but the trials were small.</li><li>Two RCTs (n = 31 and 72 respectively) showed that terbinafine and itraconazole were effective compared with placebo.</li><li>Generally, the trials were at unclear risk of bias, due to the lack of reporting of randomization techniques and allocation concealment.</li></ul></li></ul><h5>Management of severe or extensive disease in children</h5><ul><li>The recommendation on arranging dermatology referral for children with severe or extensive disease is pragmatic, based on what CKS considers to be good clinical practice. It is also supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Treating concomitant fungal nail and/or other skin infection</h5><ul><li>The recommendation on identifying and managing concomitant fungal nail and other skin infection is based on the fact that the nails, in particular, can be a source of reinfection if inadequately treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].</li></ul><!-- end field 72e33f56-a626-45a7-a3c6-8c44ca99ebf5 --><!-- end item 60581ba0-b6e8-4d6c-a7e6-ee52df56d1aa -->","subChapters":[]}]},{"id":"1be4bdac-2b29-5afd-b5fd-c822f08e2845","slug":"follow-up-referral","fullItemName":"Follow-up and referral","depth":3,"htmlHeader":"<!-- begin field 1a420101-132b-4213-8c4c-6ec8177fa096 --><h3>When should I follow up and refer?</h3><!-- end field 1a420101-132b-4213-8c4c-6ec8177fa096 -->","summary":null,"htmlStringContent":"<!-- begin item a2c14d30-bc58-4486-9856-69d8414f40c1 --><!-- begin field 1aaa54b6-874e-40ae-b936-a3655326a26c --><p><strong>Arrange for the person to be reviewed if there is an inadequate response to <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/management/management/#initial-management\">initial management</a>.</strong></p><ul><li><strong>If there are persistent signs of infection following <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/management/management/#initial-management\">topical antifungal treatment</a> in adults:</strong><ul><li>Consider and, if possible, manage any underlying cause of treatment failure. This may include:<ul><li>Non-adherence to self-care advice or the treatment regimen.</li><li>Drug-resistant or multiple organisms.</li><li>Drug interactions or adverse effects.</li><li>Reinfection from close contacts or recurrence of infection.</li><li>An immunocompromised host.</li><li>An <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/diagnosis/differential-diagnosis/\">alternative diagnosis</a>.</li></ul></li><li>Arrange for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/diagnosis/assessment/#taking-skin-samples\">skin sampling</a> for fungal microscopy and culture, and consider prescribing <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/management/management/#initial-management\">oral antifungal treatment</a> if there is:<ul><li>A positive skin sample fungal microscopy or culture result.</li><li>A strong clinical suspicion of fungal foot infection before fungal microscopy and culture results are back, depending on clinical judgement.</li><li>A negative mycology result, but clinical features are very suggestive of infection. Arrange for repeat skin sampling, and start oral antifungal treatment.</li></ul></li></ul></li><li><strong>Arrange referral to a dermatology specialist, the urgency depending on clinical judgement, if:</strong><ul><li>There is severe or extensive disease, or topical antifungal treatment is unsuccessful in a child.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field 1aaa54b6-874e-40ae-b936-a3655326a26c --><!-- end item a2c14d30-bc58-4486-9856-69d8414f40c1 -->","subChapters":[{"id":"b90751da-c3ee-52a9-ab8c-799d1ebf8a29","slug":"basis-for-recommendation-ec4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a6558798-a993-4561-b820-6a5cc1426bd7 --><h4>Basis for recommendation</h4><!-- end field a6558798-a993-4561-b820-6a5cc1426bd7 -->","summary":null,"htmlStringContent":"<!-- begin item ec4d0e62-c870-4331-a196-6cfaafcf5b0a --><!-- begin field af98757f-2a2d-47c1-b462-c4c8561df255 --><p>The recommendations on follow-up and referral are based on the Public Health England (PHE) publication <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>] and expert opinion in a review article on fungal foot infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>], on fungal infections of the skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>], and on corticosteroid-modified fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Verma, 2017</a>].</p><h5>Managing treatment failure</h5><ul><li>The recommendation on arranging skin sampling if infection is refractory to initial topical antifungal treatment is based on the PHE publication, which states that occasionally gram-negative bacterial infection can cause interdigital cracking that can mimic the appearance of fungal foot infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>]. This is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ilkit, 2014</a>].</li><li>The recommendation on considering oral antifungal treatment for failed topical treatment is extrapolated from the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Ely, 2014</a>].</li><li>The recommendations on arranging for repeat skin sampling if there are negative culture results and starting treatment if clinical appearances are very suggestive of fungal foot infection are based on expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">PHE, 2017</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>].</li></ul><h5>Arranging referral to dermatology</h5><ul><li>The recommendations on referral are extrapolated from expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Verma, 2017</a>], and are pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field af98757f-2a2d-47c1-b462-c4c8561df255 --><!-- end item ec4d0e62-c870-4331-a196-6cfaafcf5b0a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}